917022-13-0

Basic information

• Product Name: Carbamic acid, N-[[trans-4-[[(4-amino-6-chloro-2-pyrimidinyl)amino]methyl]cyclohexyl]methyl]-N-[3-[cyclohexyl[(1,1-dimethylethoxy)carbonyl]amino]propyl]-, 1,1-dimethylethyl ester
• Synonyms: Carbamic acid, N-[[trans-4-[[(4-amino-6-chloro-2-pyrimidinyl)amino]methyl]cyclohexyl]methyl]-N-[3-[cyclohexyl[(1,1-dimethylethoxy)carbonyl]amino]propyl]-, 1,1-dimethylethyl ester;N-[[trans-4-[[(4-Amino-6-chloro-2-pyrimidinyl)amino]methyl]cyclohexyl]methyl]-N-[3-[cyclohexyl[(1,1-dimethylethoxy)carbonyl]amino]propyl]carbamic acid 1,1-dimethylethyl ester;Carbamic acid,N-[[trans-4-[[(4-Amino-6-chloro-2-pyrimidinyl)ao]methyl]cyclohexyl]methyl]-N-[3-[cyclohexyl[(1,1-dimethylethoxy)carbonyl]ao]propyl]-,1,1-dimethylethyl ester
• CAS NO: 917022-13-0
• Molecular Formula: C31H53ClN6O4
• Molecular Weight: 609.25
• Product Categories: API intermediates
• Mol File: 917022-13-0.mol
• Article Data: 3

Chemical Properties

• Boiling Point: 716.452 °C at 760 mmHg
• Flash Point: 387.096 °C
• Appearance: /
• Density: 1.173g/cm³
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.555
• CAS DataBase Reference: Carbamic acid, N-[[trans-4-[[(4-amino-6-chloro-2-pyrimidinyl)amino]methyl]cyclohexyl]methyl]-N-[3-[cyclohexyl[(1,1-dimethylethoxy)carbonyl]amino]propyl]-, 1,1-dimethylethyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: Carbamic acid, N-[[trans-4-[[(4-amino-6-chloro-2-pyrimidinyl)amino]methyl]cyclohexyl]methyl]-N-[3-[cyclohexyl[(1,1-dimethylethoxy)carbonyl]amino]propyl]-, 1,1-dimethylethyl ester(917022-13-0)
• EPA Substance Registry System: Carbamic acid, N-[[trans-4-[[(4-amino-6-chloro-2-pyrimidinyl)amino]methyl]cyclohexyl]methyl]-N-[3-[cyclohexyl[(1,1-dimethylethoxy)carbonyl]amino]propyl]-, 1,1-dimethylethyl ester(917022-13-0)

Safety Data

• Hazardous Substances Data: 917022-13-0(Hazardous Substances Data)

Usage

General Description

This chemical, more commonly known as Peginterferon beta-1a, is a long-acting form of interferon used for the treatment of multiple sclerosis (MS). It is made from combining carbamic acid with several other compounds. Its complex structure includes an amino-6-chloro-2-pyrimidinyl group and a cyclohexyl group with an attached carbonyl group. It's known for its ability to hamper virus activity and help the immune system reduce inflammation, thereby slowing down the progression and reducing the frequency of relapse in patients with MS. However, like any other drugs, it may also elicit side effects like flu-like symptoms, depression, and increases in certain liver enzymes.

InChI:InChI=1/C31H53ClN6O4/c1-30(2,3)41-28(39)37(17-10-18-38(24-11-8-7-9-12-24)29(40)42-31(4,5)6)21-23-15-13-22(14-16-23)20-34-27-35-25(32)19-26(33)36-27/h19,22-24H,7-18,20-21H2,1-6H3,(H3,33,34,35,36)/t22-,23-

Upstream product

• 27687-14-5 trans 4-(tert-butyloxycarbonylamino)methylcyclohexanecarboxylic acid 
• 917021-59-1 C₁₄H₂₅NO₃ 
• 1197-18-8 trans-4-aminomethyl-cyclohexyl-carboxylic acid 
• 24424-99-5 di-tert-butyl dicarbonate 
• 166168-16-7 trans-((4-aminomethyl)cyclohexylmethyl)carbamic acid tert-butyl ester 
• 473923-79-4 trans-(4-cyanocyclohexylmethyl)carbamic acid tert-butyl ester 
• 749866-15-7 trans-4-[[(tert-butoxycarbonyl)amino]methyl]cyclohexanecarboxylic acid amide 
• 10132-07-7 4-amino-2,6-dichloropyrimidine 
• 917021-76-2 C₂₇H₅₁N₃O₄ 

Downstream Products

• 1191450-19-7 (x)BrH*C₂₇H₅₁N₈O₃P 

Relevant articles and documents

MOBILIZING CELLS EXPRESSING A TYPE 4 CXC CHEMOKINE RECEPTOR WITH 4-AMINO PYRIMIDINE COMPOUNDS

A method of mobilizing cells expressing the type 4 CXC chemokine receptor into the peripheral circulation by contacting them with an effective amount of a compound of formula (I) shown below (each variable in the formula being defined in the Specification

Pyrimidine compounds

This invention relates to a method for treating inflammatory diseases or immune diseases, developmental or degenerative diseases, or tissue injuries. The method includes administering to a subject in need thereof an effective amount of one or more compounds of formula (I). Each variable in this formula is defined in the specification.